Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selonabant - Anebulo Pharmaceuticals

Next Previous
Drug Profile

Selonabant - Anebulo Pharmaceuticals

Alternative Names: ANEB 001; V-24343

Latest Information Update: 30 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer Anebulo Pharmaceuticals; Vernalis
  • Class Drug withdrawal therapies; Obesity therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Substance-related disorders
  • Discontinued Obesity

Most Recent Events

  • 25 Sep 2025 Phase-I clinical trials in Substance-related disorders (In volunteers) in USA (IV)
  • 13 May 2025 Anebulo Pharmaceuticals plans a single ascending dose (SAD) phase I trial for Substance-related disorders (In adults, In volunteers) in USA (IV), in the third quarter of 2025
  • 23 Dec 2024 Anebulo completes a meeting with the US FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top